AI Drug Development Startup Genesis Raises $200 Million for AI Drug Development

California-based startup Genesis Therapeutics has successfully raised $200 million in a Series B funding round, with the funds earmarked for advancing the clinical trials of its AI-driven drug projects and expanding research into new areas. This round of financing was co-led by Andreessen Horowitz and an undisclosed life sciences investor. Genesis Therapeutics focuses on utilizing artificial intelligence to model and predict the properties of proteins and their molecular partners, having secured over $280 million in cumulative funding to date. The company's work has attracted the attention of pharmaceutical giants Eli Lilly and Roche, with whom they are collaborating on drug development.

Anthropic Raises Funding at a Valuation of $90 Billion Targeting $3 Billion

The AI company Anthropic is planning to raise $3 billion in funding, with a pre-money valuation of $90 billion, reflecting strong market confidence in its future prospects. Negotiations are progressing quickly, and the deal is expected to be completed as early as月底, but specific terms of the agreement are still under discussion and have not been finalized yet.

Liang Wenfeng Invests 20 Billion! DeepSeek Launches Record-Breaking $5 Billion Funding Round, V4.1 Set for June

The domestic large model sector has witnessed a capital storm, with DeepSeek (Deep Seek) initiating its first major funding round targeting an amount of 5 billion yuan, which, if successful, would break the industry record. Notably, the lead investor is not a venture capital firm or an internet giant, but the founder Liang Wenfeng himself, who has invested the highest personal amount, demonstrating his strong confidence in the company.

The Shadow of OpenAI and Anthropic: Why Cursor's $5 Billion Funding Round Was Rejected by Big Tech Investors

AI programming company Cursor faced obstacles in its quest for several billion dollars in funding, with its $5 billion valuation deterring several later-stage investment firms. Previously, SpaceX had shown interest in acquiring it for $6 billion, but top funds including Iconiq have clearly rejected the offer. The main reason for the cold funding climate is that global capital has already completed its initial setup in the AI sector.

High-end AI company Upscale AI plans to raise new funding with a valuation of 2 billion USD

Artificial intelligence infrastructure company Upscale AI is in talks for a new round of funding, targeting a valuation of 2 billion USD and aiming to raise between 180 million and 200 million USD. This will be its third round of funding in seven months, following a 200 million USD Series A funding and a 100 million USD seed funding. Investors include well-known institutions such as Tiger Global.

AI Drug Development Startup Genesis Raises $200 Million for AI Drug Development

Related Recommendations

Anthropic Raises Funding at a Valuation of $90 Billion Targeting $3 Billion

Liang Wenfeng Invests 20 Billion! DeepSeek Launches Record-Breaking $5 Billion Funding Round, V4.1 Set for June

The Shadow of OpenAI and Anthropic: Why Cursor's $5 Billion Funding Round Was Rejected by Big Tech Investors

High-end AI company Upscale AI plans to raise new funding with a valuation of 2 billion USD

AI Learning App Gizmo Surpasses 13 Million Users and Secures $22 Million in Funding to Focus on the Higher Education Market